Little Progress Made in Insuring Patient Safety (CME/CE)

(MedPage Today) — A decade after the Institute of Medicine’s report cataloging iatrogenic injury, harm resulting from medical care is still common with few signs of improvement, at least at 10 North Carolina hospitals, researchers found.

Experts Assess Health Risks of Airport Full-Body Scanners

(MedPage Today) — With the Transportation Security Administration (TSA) ramping up its use of full-body scanners in airports just at the busiest travel time of the year, passengers are extra cautious about what health risks, if any, are posed by the new scanners.

Appeals Court Overturns Prescriber Data-Mining Law

(MedPage Today) — A federal appeals court has ruled that a Vermont law restricting the commercial use of physician prescribing data is unconstitutional.

Well-Being Improves After Retirement (CME/CE)

(MedPage Today) — Leaving the work force may improve one’s health, a large, French cohort study showed.

Big Jump in Diabetes Incidence Expected in Next Decade

(MedPage Today) — By the year 2020, 52% of adults in the U.S. could be prediabetic or diabetic, up from about 40% today, a new report predicted.

Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients

Researchers with UCLA’s Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse.

Glycotex receives cash grant under QTDP program to develop GLYC-101 Gel

Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program.

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

RCSI Research Highlights Lessons And Opportunities In Drug Development

A research review carried out by the Royal College of Surgeons in Ireland (RCSI) and published in ‘Nature Reviews and Drug Discovery’ (October 2010) has highlighted the lessons, opportunities and recent developments in the area of drug development for cardiovascular disease, auto-immune disorders and multiple sclerosis…